FDA Approves Mycamine
Mycamine Approved for Candida Infections
Mycamine (micafungin sodium) is a member of a new class of antifungal agents, the echinocandins, which inhibit cell-wall synthesis. Mycamine is used for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and the treatment of esophageal candidiasis.Posted: March 2005
Related articles
- FDA Approves Expanded Indication of Mycamine (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age - January 8, 2020
- FDA Approves Pediatric Indication for Astellas' Mycamine (micafungin sodium) for Injection - June 24, 2013
- FDA Approves Additional Indication for Astellas' Mycamine - January 23, 2008
- Fujisawa Healthcare, Inc. Submits NDA For Mycamine For Treatment Of Esophageal Candidiasis - April 27, 2004
Mycamine (micafungin sodium) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
